Ready for the change? — PTI provides guidance on new EU Clinical Trial Regulation
![](/46/pdcnewsitem/03/81/53/pti.jpg)
The EU-CTR replaces the EU Clinical Trials Directive and is designed to improve harmonisation on conducting clinical trials of medicinal products for human use throughout the EU.
Pharmaceutical Training International (PTI) is providing detailed guidance on the new EU Clinical Trial Regulation (EU-CTR), which applies from 28 May 2016. Making sure clinical trial and regulatory affairs professionals are up-to-date and prepared, PTI is hosting a convenient and cost-effective 2-hour webinar e-course at 2:30 PM (UK) on Wednesday 2 December. Industry expert Adriaan Fruijtier, Director Regulatory Affairs, CATS Consultants GmbH, and formerly Head of the Oncology Group within Global Regulatory Affairs at Bayer AG and Bayer Corporation, will host this event.
The EU-CTR replaces the EU Clinical Trials Directive and is designed to improve harmonisation on conducting clinical trials of medicinal products for human use throughout the EU. It brings with it significant procedural changes for both trial authorisation and conduct for which individuals and organisations must be prepared. In PTI’s webinar e-course titled ‘Guidance on the New Clinical Trial Regulation’ Adriaan Fruijtier will provide a comprehensive examination of the new regulation. He will cover the scope, authorisation procedures, low intervention clinical trials, the EU portal and database, transparency requirements, key timelines and milestones, and a helpful comparison between the new regulation and the existing directive. With over 20 years’ experience in pharma regulatory affairs, Adriaan will also be available for a valuable live question and answer session at the end of the webinar.
“This really is essential information for anyone working in clinical trials and regulatory affairs,” said PTI’s Managing Director, Rosie Bernard. “With this webinar e-course we wanted to make it as easy as possible for professionals to access the most up-to-date and useful guidance to ensure a smooth transition to the EU-CTR next year. Adriaan is an expert with a great deal of experience in pharma regulatory affairs, ranging from the European Medicines Agency to the likes of Glaxo and Novartis, so I can’t think of anyone better placed to deliver this guidance. It’s also a great opportunity for professionals to address specific queries with him personally in the live Q&A session.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance